Effect of vesnarinone on cardiac function in patients with severe congestive heart failure
| Autor: | Thomas G. DiSalvo, G. William Dec, Diane Cocca-Spofford, Marc J. Semigran, Michael H. Picard, Marielle Scherrer-Crosbie |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Male
Cardiac function curve medicine.medical_specialty Cardiotonic Agents Heart disease medicine.medical_treatment Ventricular Function Left Muscle hypertrophy chemistry.chemical_compound Internal medicine medicine Humans cardiovascular diseases Aged Vesnarinone Heart Failure Chemotherapy Ejection fraction business.industry Hemodynamics Middle Aged medicine.disease chemistry Echocardiography Pyrazines Heart failure Quinolines cardiovascular system Cardiology Female Cardiology and Cardiovascular Medicine Complication business |
| Zdroj: | American Heart Journal. 136:769-777 |
| ISSN: | 0002-8703 |
| Popis: | Vesnarinone has yielded controversial results on morbidity in patients with congestive heart failure. We tested the hypothesis that vesnarinone may have a beneficial effect on cardiac remodeling and function.Thirty-four patients with left ventricular ejection fraction (LVEF)30% (17 treated with vesnarinone) underwent an echocardiography at baseline and at 12+/-5 months. Left ventricular end-diastolic and end-systolic volume, mitral regurgitation, diastolic filling, and right ventricular area change were quantified and compared.When the vesnarinone group was considered as a whole, there was no significant effect of vesnarinone on cardiac systolic and diastolic function or remodeling. However, an increase in LVEF7% was observed in six of the vesnarinone patients and none of the control group. Vesnarinone improved right and left ventricular systolic function significantly in patients with initial LVEF25%.In severe congestive heart failure, vesnarinone induces variable responses but improves biventricular performance in patients with the most impaired initial function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect